[go: up one dir, main page]

WO2002069932A1 - Compositions moussantes - Google Patents

Compositions moussantes Download PDF

Info

Publication number
WO2002069932A1
WO2002069932A1 PCT/JP2002/001955 JP0201955W WO02069932A1 WO 2002069932 A1 WO2002069932 A1 WO 2002069932A1 JP 0201955 W JP0201955 W JP 0201955W WO 02069932 A1 WO02069932 A1 WO 02069932A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
carbonate
hydrochloride
sodium
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001955
Other languages
English (en)
Japanese (ja)
Inventor
Toshinori Tanaka
Tomio Nakano
Shogo Izumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP2002569110A priority Critical patent/JP4165224B2/ja
Publication of WO2002069932A1 publication Critical patent/WO2002069932A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Definitions

  • the present invention relates to a composition having a foaming function.
  • compositions with foaming functions are widely used in products such as pharmaceuticals, foods, denture cleaners, contact lens cleaners, baths, and disinfectants (“Powder and compression molding technology”, p. 7 1, 'Nikkan Kogyo Shimbun).
  • This function is exerted by the reaction of the constituent acids and carbonates with water to generate carbon dioxide.
  • acid and carbonate if no countermeasures are taken, the reaction proceeds by the moisture in the atmosphere, and furthermore, the reaction progresses in a chain by the generated water, and the appearance and collapse of the composition It is feared that it will have a great effect on the quality such as solubility and dissolution. In general, this problem has been solved by devising packaging technology.
  • a water-soluble polymer is mainly used as an inert carrier for a solid dispersion, but most water-soluble polymers have a property of causing swelling and the like when contacted with water and increasing viscosity. Such a viscous action may cause a decrease in the disintegration of the preparation, and may impair the effect of improving the solubility, which is a characteristic of the solid dispersion. Therefore, when developing pharmaceuticals as ordinary pharmaceuticals, the weight ratio of solid dispersions is currently limited to about 25%, and it is difficult to develop pharmaceuticals containing more solid dispersions. .
  • An object of the present invention is to provide a physically and chemically stable foamable composition while maintaining sufficient foamability and disintegration.
  • Another object of the present invention is to provide an effervescent pharmaceutical composition containing more solid dispersion by improving the disintegration of a pharmaceutical preparation containing the solid dispersion.
  • the present inventors have conducted intensive studies, and as a result, by including an acid in the adsorptive substance, the contact with the carbonate is reduced, and the adsorbent absorbs the water generated by the reaction. As a result, it has been found that the above object can be achieved, and the present invention has been completed.
  • Examples of the present invention include the following.
  • the acid is selected from the group consisting of tartaric acid, potassium hydrogen tartrate, citric anhydride, organic acid which is sodium dihydrogen citrate or malic acid, or inorganic acid which is hydrochloric acid, sulfuric acid or phosphoric acid.
  • the adsorptive substance is light caustic anhydride, hydrous silicon dioxide,
  • a foamable composition comprising the adsorptive substance and the carbonate according to any of (1), (2), (3) or (4) above,
  • An effervescent pharmaceutical composition comprising the adsorptive substance, a carbonate and a pharmaceutical according to any one of the above (1), (2), (3) or (4),
  • An effervescent pharmaceutical composition comprising the adsorptive substance, carbonate and solid pharmaceutical dispersion according to any of (1), (2), (3) or (4) above, (8) (5), (6) or (7) above, wherein the carbonate is one or more selected from the group consisting of sodium hydrogencarbonate, sodium carbonate, carbonated carbonate, magnesium carbonate and calcium carbonate.
  • a pharmaceutical preparation comprising the effervescent pharmaceutical composition according to any of (6), (7) or (8) above,
  • the adsorptive substance is a porous substance having a large specific surface area and an adsorptivity, and refers to a substance having the same adsorptivity as activated carbon.
  • the adsorbing substance is not particularly limited as long as it can contain an acid, and preferably has a property of adsorbing moisture.
  • Examples of the adsorptive substance that can be used in the present invention include light silicic anhydride, hydrated silicon dioxide, calcium silicate, magnesium silicate and the like. '
  • Examples of the acid that can be used in the present invention include maleic acid, fumaric acid, succinic acid, oxalic acid, malonic acid, adipic acid, benzoic acid, salicylic acid, ascorbic acid, sorbic acid, nicotinic acid, phenylacetic acid, and lingoic acid.
  • a pharmaceutically acceptable acid is preferable.
  • tartaric acid, potassium hydrogen tartrate, citric anhydride, sodium dihydrogen citrate, and malic acid are more preferred.
  • Examples of the carbonate that can be used in the present invention include lithium carbonate, ammonium carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, ammonium hydrogen carbonate, sodium tricarbonate, ammonium tricarbonate, and sodium hydrogen carbonate.
  • Lithium, sodium carbonate, potassium carbonate, magnesium carbonate, carbonated calcium and the like can be mentioned.
  • a pharmaceutically acceptable carbonate is preferable.
  • sodium hydrogen carbonate, sodium carbonate, sodium carbonate, magnesium carbonate, and sodium carbonate are more preferred.
  • the medicament that can be used in the present invention is not particularly limited, but a poorly soluble medicament having a solubility of not more than g / m 1 in the first or second liquid of the Japanese Pharmacopoeia No. 13 at 25 ° C. It is preferable to use a poorly soluble drug having a solubility of 1 OO / ig Zm 1 or less in the first solution or the second solution of the Japanese Pharmacopoeia No. 13 at 25 ° C.
  • the following medicines can be mentioned as specific examples.
  • Snorrepiride settraxate hydrochloride, gefarnate, ilsogladine maleate, cimetidine, ranitidine hydrochloride, famotidine, nizatidine, mouth xantidine acetate hydrochloride, sodium azulene sulfonate.
  • Difenprodil tartrate cinepacide maleate, cyclanderate, cinnaridine, pentoxifylline.
  • Teofirin Aminofilin, Methylephedrine hydrochloride, Propoterol hydrochloride, Trimetoquinol hydrochloride, Codine phosphate, Sodium chromatoglyphate, Tranilus Dextromethorphan hydrobromide, dimethomorphine phosphate, croptinolate hydrochloride, fominovene hydrochloride, benproperin phosphate, 'tividin hibenzanate, eprazinone hydrochloride, cropropane chloride Fedanol, effeline hydrochloride, nosin pin, norebetapentene citrate, oxserazine tannate, and isoaminol quinate.
  • Procyanamide hydrochloride disoviramide, azimarin, quinidine sulfate, aplidine hydrochloride, propafenone hydrochloride, mexiletine hydrochloride.
  • Alopurinol probenecid, conorechtin, snorefinpirazone, benzpromarone, puko mouth.
  • Clonorefeniramine maleate clemastine fumarate, mequitazine, arylemazine tartrate, cycloheptadine hydrochloride.
  • 2 Antiemetic. 'Difudol hydrochloride, metoclopramide, domperidone, betahistine mesylate, trimeptin maleate.
  • Vitamin B1, vitamin B2, vitamin B6, vitamin B1 2, vitamin C, folic acid is Vitamin B1, vitamin B2, vitamin B6, vitamin B1 2, vitamin C, folic acid.
  • the inert carrier for the solid dispersion that can be used in the present invention includes, for example, methinoresenorelose, etinoresenorelose, hydroxyxetine, chinoresenolerose, hydroxypropyl cellulose, hydroxypropyl propyl cellulose, hydroxypropinolemethylsenorello.
  • preferred are hydroxypine pinoresenorelose, hydroxypropinolemethy / resenorelose, polyvinylpyrroli, and dong.
  • the mixing ratio of acid and carbonate varies depending on the type of acid and carbonate used, the presence or absence of other additives, etc., but an appropriate weight ratio of 0.1 to 10 is appropriate. , 0.3 to 4 are preferred. More preferably, it is 0.5 to 2.
  • the mixing ratio of the acid in the adsorptive substance containing the acid '(adsorptive substance containing the acid Z acid) is not particularly limited.
  • the preferred compounding ratio is Although it depends on the type of the active substance and the acid, etc., a weight ratio of 0.01 to 0.9 is appropriate. ⁇ 0.8 is preferred. More preferably, it is 0.3 to 0.7.
  • the mixing ratio of the adsorbing substance containing an acid is not particularly limited.
  • the preferred blending ratio varies depending on the type of carbonate used, the presence or absence of other additives, and the like, but the weight ratio is preferably 0.0'1 to 0.8, and 0.0 2-0.4 is preferred. More preferably, it is from 0.03 to 0.2.
  • the blending ratio of the drug in the composition according to the present invention (the whole pharmaceutical composition) varies depending on the drug used, the type of acid and carbonate, the presence or absence of other additives, and the like, but the weight ratio is 0.00. 0 :! To 0.9 is suitable, and 0.001 to 0.7 is preferred.
  • the compounding ratio of the drug (pharmaceutical / pharmaceutical solid dispersion) in the solid pharmaceutical dispersion according to the present invention varies depending on the inert carrier used, the type of the pharmaceutical, and the like. 9 is suitable and 0.02 to 0.6 force S is preferred. More preferably, it is 0.05 to 0.5.
  • the mixing ratio of the solid pharmaceutical dispersion (the solid pharmaceutical dispersion / the whole composition) in the composition according to the present invention depends on the type of the inert carrier used, the medicine, the acid and the carbonate, and the presence or absence of other additives.
  • the weight ratio is suitably from 0.01 to 0.9, and is preferably from 0.1 to 0.8. More preferably, it is 0.25 to 0.6.
  • additives can be added to the composition according to the present invention as needed.
  • additives include, for example, excipients (eg, milk bran, corn starch, crystalline cellulose, D-mannitol, calcium hydrogen phosphate), disintegrants (eg, low-substituted hydroxy) Propyl senorelose, canolemeloose, closkanolemeloose sodium, potassium noremelose calcium), lubricants (eg, magnesium stearate, stearate. Calcium acid, talc), coloring agents (eg, iron sesquioxide, yellow sesquioxide) iron.
  • excipients eg, milk bran, corn starch, crystalline cellulose, D-mannitol, calcium hydrogen phosphate
  • disintegrants eg, low-substituted hydroxy
  • Propyl senorelose canolemeloose
  • closkanolemeloose sodium potassium noremelose calcium
  • lubricants eg
  • An appropriate amount of such an additive in the composition is 50% by weight or less.
  • the adsorptive substance contain an acid
  • a so-called liquid adsorption method or a melt adsorption method can be used.
  • it can be carried out by dissolving an acid in an appropriate solvent, kneading with an adsorptive substance, and drying (liquid adsorption method).
  • kneading with an adsorptive substance
  • drying liquid adsorption method
  • heating, melting, and kneading can be performed (melt adsorption method).
  • the solvent used here is not particularly limited as long as it dissolves the acid used and does not dissolve the adsorptive substance, but water or ethanol is preferred.
  • the “foamable composition containing an adsorbing substance containing an acid and a carbonate” according to the present invention is, for example, an adsorbing substance containing an acid and a carbonate produced by the method described above, and other substances as required. It can be produced by mixing various additives by a conventional method.
  • granules are obtained by dissolving an acid in an appropriate solvent, kneading with an adsorbent substance, granulating, drying and sieving.
  • the desired foamable composition can be produced by mixing the granules and the carbonate in a conventional manner.
  • the “effervescent pharmaceutical composition containing an adsorbent substance containing an acid, a medicine, and a carbonate” according to the present invention contains, for example, an acid produced by the above method. It can be produced by mixing adsorbents, pharmaceuticals, carbonates, and other various additives as necessary by a conventional method.
  • granules are obtained by kneading with an adsorbent substance, granulating, drying, and sifting.
  • Granules are obtained by using a binder such as a vinyl alcohol solution, dried and filtered to obtain granules, and these granules and carbonates are mixed in a conventional manner to produce the desired effervescent pharmaceutical composition. can do.
  • the pharmaceutical solid dispersion according to the present invention can be produced by a conventional method such as a so-called solvent method, a melting method, and a mixing and pulverizing method (mechanochemical method).
  • twin-screw extruder having a special screwing element called a kneading element, preferably a fully meshing co-rotating twin-screw extruder equipped with a euding element
  • the medicine and the pharmaceutical are continuously used.
  • Manufactured by batch processing such as mixing, kneading, pulverizing, and shearing with a water-soluble polymer (for example, PCTO 92/18 106, Japanese Patent Application Laid-Open No. 5-26262). can do.
  • the “adsorbable substance containing an acid, a solid pharmaceutical dispersion containing a drug, and the effervescent pharmaceutical composition containing a carbonate” according to the present invention include, for example, an adsorbable substance containing an acid and a solid drug dispersion containing an acid produced by the above method. Manufactured by mixing the body, carbonate, and other additives as needed be able to. '
  • Lactose 40 Og and corn starch 20 g was charged into a fluid bed granulator and mixed for 3 minutes. Thereafter, 570 g of an aqueous solution of HPMC 2911% was sprayed to perform granulation. This granulated product was sized (0.140 ⁇ m punch screen) using a Comil. Separately, 150 g of calcium silicate was put into a kneader-granulator, kneaded with 100 g of a 30% aqueous solution of citric acid, and then 10 g of calcium silicate was added, followed by kneading. . This kneaded product was pulverized with a feather mill. After drying this with a fluid bed granulator, it was sieved with 24 mesh.
  • the granules, the sample obtained in Reference Example 2 (1600 g), sodium hydrogen carbonate (400 g), L-HPC (56 g) and magnesium stearate (44 g) were charged into a Bohle container mixer. After mixing for 0 minutes, the mixture was compression-molded with a breaker using a punch machine with a tablet size of 390 nxg, a tablet diameter of 11 mm, and 1000 to 150 kg / punch to obtain tablets.
  • the coating A solution HPMC 291.40 g, propylene glycol cornole 8 g, Ojiride
  • Tablets were coated using the whole amount of a solution of 8 g of titanium and 8 g of talc in a water: ethanol mixture (1: 1), which was suspended in 5300 ml, to produce film tablets. .
  • the milk bran (740 g) was charged into a fluid bed granulator and mixed for 3 minutes. Thereafter, 43 g of a 7% aqueous solution of PVA was sprayed to perform granulation.
  • the granulated product was sized by a Comill (a punch screen of 140 ⁇ m).
  • 240 g of calcium silicate was charged into a kneader-granulator, kneaded with 570 g of a 35% aqueous solution of tartaric acid, and 10 g of calcium silicate was added thereto. went. This kneaded product was pulverized with a feather mill. This was dried with a fluid bed granulator, and then sieved with a sieve of 24 mesh.
  • the granules 1200 g of the sample obtained in Reference Example 2, 1200 g of sugar, 600 g of L_HPC, 450 g of sodium hydrogen carbonate and 50 g of magnesium stearate were placed in a Pole container mixer. Charged and mixed for 20 minutes. This was compression-molded with a tableting machine using a punch with a diameter of 350 mg, a tablet diameter of 11 mm, 900 to 1200 kg, and a tablet was obtained. Furthermore, tablet coating was performed using the entire amount of coating solution B using a doria coater to produce film tablets.
  • the granules, 800 g of the sample obtained in Reference Example 2, 160 g of L-HPC and 20 g of magnesium stearate were put into a Bohle container mixer, and after mixing for 20 minutes, the mixture was beaten.
  • One tablet was 39 Omg in a tablet machine, tablet diameter was 11 mm, 900 to 1200 kg / compressed with a punch to obtain tablets.
  • tablet coating was performed using the entire amount of coating solution A using a doria coater to produce film tablets.
  • Example 1 and Comparative Example 1 The tablets obtained in Example 1 and Comparative Example 1 were packaged by heat sealing a 3 x 3 cm aluminum sheet and polycello, respectively, at 40 ° C and a relative humidity of 75% RH. The swelling of the packaging container at was observed. Further, the tablets selected in Example 1 and Comparative Example 1 were set on a sinker in a dissolution test of the Japanese Pharmacopoeia General Test Method. The tablets were put into 900 ml of purified water preheated to 37 ° C, and the time until no sample was seen in the sinker was measured.
  • Example 5 and Comparative Example 2 Each of the tablets obtained in Example 5 and Comparative Example 2 was packaged by heat-sealing a 3 ⁇ 3 cm aluminum sheet and a polycete mouth, at 40 ° C. and a relative humidity of 75 ° C. Observations were made on the swelling of the packaging container in a% RH environment. Further, the tablets selected in Example 2 and Comparative Example 5 were set on a sinker in a dissolution test of the Japanese Pharmacopoeia General Test Method. The tablets were put into 900 ml of purified water preheated to 37 ° C, and the time until no sample was seen in the sinker was measured.
  • Test Example 3 One tablet of each of the preparations obtained in Example 2 and Comparative Example 3 was used with 900 ml of test solution (1% sodium lauryl sulfate) in Japanese Pharmacopoeia General Test Method Dissolution Test 2 Dissolution test was performed according to the method (paddle method). After the start of the test, 5 ml of the test solution was withdrawn over time and filtered with a DC 0.45 im membrane filter. The filtrate 1 m 1 Ri accurately adopt 0 Shiguma0iota and quantification was performed on the eluted amount by HPLC was added an internal standard.
  • the present invention it is possible to provide a foamable composition having improved physical and chemical stability against moisture as described above without using a special packaging technique. Further, according to the present invention, the pharmaceutical solid dispersion can be contained in the composition in an amount of 25% by weight or more, for example, 60% by weight, and the dissolution property of 85% or more in 15 minutes is ensured. Thus, it is possible to provide a quick-release preparation utilizing the characteristics of the solid dispersion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions moussantes qui présentent une stabilité physique et chimique supérieure tout en conservant des propriétés moussantes et de désintégration suffisantes. L'invention vise également à améliorer les propriétés de désintégration de préparations médicales contenant une dispersion solide, pour obtenir des compositions médicales moussantes contenant une quantité accrue de dispersion solide. Les compositions moussantes sont caractérisées en ce qu'un acide est contenu dans un adsorbant pour empêcher tout contact direct de l'acide avec un carbonate et permettre une absorption d'eau par l'adsorbant.
PCT/JP2002/001955 2001-03-05 2002-03-04 Compositions moussantes Ceased WO2002069932A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002569110A JP4165224B2 (ja) 2001-03-05 2002-03-04 発泡性組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-59988 2001-03-05
JP2001059988 2001-03-05

Publications (1)

Publication Number Publication Date
WO2002069932A1 true WO2002069932A1 (fr) 2002-09-12

Family

ID=18919472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001955 Ceased WO2002069932A1 (fr) 2001-03-05 2002-03-04 Compositions moussantes

Country Status (2)

Country Link
JP (1) JP4165224B2 (fr)
WO (1) WO2002069932A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006046623A1 (ja) * 2004-10-25 2008-05-22 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
CN102451661A (zh) * 2010-10-15 2012-05-16 中国石油化工股份有限公司 一种硅酸镁吸附剂的处理方法
US8518441B2 (en) 2003-11-14 2013-08-27 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
JP2014193842A (ja) * 2013-01-22 2014-10-09 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
EP3193843A1 (fr) * 2014-09-17 2017-07-26 Steerlife India Private Limited Composition effervescente et son procédé de fabrication
JP2021501166A (ja) * 2017-10-31 2021-01-14 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 崩壊が改善された経口用固形製剤組成物及びその製造方法
JP2023538917A (ja) * 2020-08-20 2023-09-12 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポイクオリンを含む発泡性組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61150062U (fr) * 1985-03-11 1986-09-17
US4968433A (en) * 1989-12-06 1990-11-06 The Dow Chemical Company Removal of organic cations from polar fluids
US5891324A (en) * 1996-03-04 1999-04-06 Kuraray Chemical Co., Ltd. Acid-containing activated carbon for adsorbing mercury from liquid hydrocarbons
JP2002079085A (ja) * 2000-09-04 2002-03-19 Masayuki Muto 吸着剤、ガス放散抑制方法、建築用材、家具用材および内装材

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61150062U (fr) * 1985-03-11 1986-09-17
US4968433A (en) * 1989-12-06 1990-11-06 The Dow Chemical Company Removal of organic cations from polar fluids
US5891324A (en) * 1996-03-04 1999-04-06 Kuraray Chemical Co., Ltd. Acid-containing activated carbon for adsorbing mercury from liquid hydrocarbons
JP2002079085A (ja) * 2000-09-04 2002-03-19 Masayuki Muto 吸着剤、ガス放散抑制方法、建築用材、家具用材および内装材

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518441B2 (en) 2003-11-14 2013-08-27 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
JPWO2006046623A1 (ja) * 2004-10-25 2008-05-22 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
JP4782695B2 (ja) * 2004-10-25 2011-09-28 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
CN102451661A (zh) * 2010-10-15 2012-05-16 中国石油化工股份有限公司 一种硅酸镁吸附剂的处理方法
JP2014193842A (ja) * 2013-01-22 2014-10-09 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
EP3193843A1 (fr) * 2014-09-17 2017-07-26 Steerlife India Private Limited Composition effervescente et son procédé de fabrication
US11576855B2 (en) 2014-09-17 2023-02-14 Steerlife India Private Limited Effervescent composition and method of making it
JP2021501166A (ja) * 2017-10-31 2021-01-14 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 崩壊が改善された経口用固形製剤組成物及びその製造方法
JP2022153652A (ja) * 2017-10-31 2022-10-12 サムヤン、ホールディングス、コーポレーション 崩壊が改善された経口用固形製剤組成物及びその製造方法
JP7458317B2 (ja) 2017-10-31 2024-03-29 サムヤン、ホールディングス、コーポレーション 崩壊が改善された経口用固形製剤組成物及びその製造方法
US11980610B2 (en) 2017-10-31 2024-05-14 Samyang Holdings Corporation Oral solid dosage form composition having improved disintegration and preparation method therefor
JP2023538917A (ja) * 2020-08-20 2023-09-12 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポイクオリンを含む発泡性組成物

Also Published As

Publication number Publication date
JP4165224B2 (ja) 2008-10-15
JPWO2002069932A1 (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
JP6014044B2 (ja) 迅速分散顆粒、口腔内崩壊錠、および方法
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CN103025317B (zh) 钠布啡类制剂及其用途
WO2000024423A1 (fr) Particules a liberation prolongee
KR20110097829A (ko) 낮은 ｐＨ에서 불량한 수용해도를 갖는 이온화가능한 활성제의 제어 방출을 위한 고체 조성물, 및 그의 사용 방법
JP2002526437A (ja) アジテーション非依存性薬学的マルチプル−ユニット持効性製剤およびその製法
TW201041608A (en) Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
JP2001511156A (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
JP2006506362A (ja) 胃内保持型レボドパデリバリー形態
JP2011148816A (ja) 口腔内速崩壊性錠
EP3791867A1 (fr) Particule creuse contenant un médicament
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
EP3294719B1 (fr) Pyroglutamate de vortioxetine
KR20010082250A (ko) 약물을 함유하는 구형 미립자의 제조 방법
EP3620156A1 (fr) Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées
JP5123207B2 (ja) 薬剤組成物及び製造法
JP4691925B2 (ja) 圧縮成型製剤の製造方法
WO2002069932A1 (fr) Compositions moussantes
CN1529587A (zh) 含有粪便软化剂泊洛沙姆和包有肠溶衣的比沙可定颗粒的药物组合物
WO2002024168A1 (fr) Procede de production d'une dispersion solide medicinale
CN100389750C (zh) 改善溶解性和流动性的医药组合物
WO2020111089A1 (fr) Composition pharmaceutique
JPH0710747A (ja) 固形製剤およびその製造方法
WO2015199115A1 (fr) Composition pharmaceutique à administration orale
JP2003095980A (ja) 潮解性物質を含有する組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP KR RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002569110

Country of ref document: JP

122 Ep: pct application non-entry in european phase